Diagnostic difficulties in myasthenia gravis

Perioperative Diaphragm Dysfunction

Diaphragm Dysfunction (DD) is a respiratory disorder with multiple causes. Although both unilateral and bilateral DD could ultimately lead to respiratory failure, the former is more common. Increasing research has recently delved into perioperative diaphragm protection. It has been established that DD promotes atelectasis development by affecting lung and chest wall mechanics. Diaphragm function must be specifically assessed for clinicians to optimally select an anesthetic approach, prepare for adequate monitoring, and implement the perioperative plan. Recent technological advancements, including dynamic MRI, ultrasound, and esophageal manometry, have critically aided disease diagnosis and management. In this context, it is noteworthy that therapeutic approaches for DD vary depending on its etiology and include various interventions, either noninvasive or invasive, aimed at promoting diaphragm recruitment. This review aims to unravel alternative anesthetic and operative strategies that minimize postoperative dysfunction by elucidating the identification of patients at a higher risk of DD and procedures that could cause postoperative DD, facilitating the recognition and avoidance of anesthetic and surgical interventions likely to impair diaphragmatic function.

Reversible spontaneous EMG activity during myasthenic crisis: Two case reports

Background

Myasthenia Gravis (MG) is an antibody-mediated autoimmune neuromuscular disorder, clinically presenting with fatigable variable muscle weakness. Typical electrodiagnostic findings are a decremental response to repetitive nerve stimulation with post-exercise facilitation, and motor unit instability expressed as increased jitter on single fibre-EMG. Presence of spontaneous activity on standard EMG is traditionally considered inconsistent with a diagnosis of MG and would direct the differential diagnosis towards a primary denervating or usually inflammatory myopathic process.Case reportWe herein present two patients with progressive severe bulbar symptomatology, whose needle-EMG examinations showed spontaneous activity and led to erroneous initial diagnoses of inflammatory myopathy and anterior horn cell disease respectively. Follow-up neurophysiological investigations, positive anti-AchR titres and good response to IVIg and steroids eventually established the diagnosis of Myasthenia Gravis.

Conclusions

Clinically severe Myasthenia Gravis can potentially present with spontaneous activity on EMG, mimicking acute myopathic or neurogenic processes. This can prove particularly perplexing and cause significant delays in the diagnosis and treatment of a myasthenia relapse.

Diaphragm Dysfunction: Diagnostic Approaches and Management Strategies

The diaphragm is the main inspiratory muscle, and its dysfunction can lead to significant adverse clinical consequences. The aim of this review is to provide clinicians with an overview of the main causes of uni- and bi-lateral diaphragm dysfunction, explore the clinical and physiological consequences of the disease on lung function, exercise physiology and sleep and review the available diagnostic tools used in the evaluation of diaphragm function. A particular emphasis is placed on the clinical significance of diaphragm weakness in the intensive care unit setting and the use of ultrasound to evaluate diaphragmatic action.

Myasthenia gravis and amyotrophic lateral sclerosis: A pathogenic overlap

The aim was to examine potential joint disease mechanisms for myasthenia gravis (MG) and amyotrophic lateral sclerosis (ALS) through the examination of long-term patient cohorts for comorbidity. Recent studies support early involvement of the neuromuscular junction in ALS patients with subsequent degeneration of motor neurons. Medical records at Haukeland University Hospital from 1987 to 2012 were examined for International Classification of Diseases diagnostic codes for MG and ALS. Sera were re-tested for antibodies to acetylcholine receptor, titin, MuSK and GM1. We report one patient with both MG and ALS, and another 3 patients with suggestive evidence of both conditions. This is far more than expected from prevalence and incidence figures in this area if the disorders were unrelated. Our data suggest that immunological mechanisms in the neuromuscular junction are relevant in ALS pathogenesis. Attention should be given to possible therapeutic targets in the neuromuscular junction and muscle in ALS patients.

Reversible man-in-the-barrel syndrome in myasthenia gravis

Man-in-the-barrel syndrome (MBS) is an uncommon presentation due to bilateral, predominantly proximal muscle weakness that has not been described to be associated with myasthenia gravis. We describe a case of myasthenia gravis presenting as MBS. Additionally, he had significant wasting of the deltoids bilaterally with fibrillations on electromyography (EMG) at rest and brief duration (3-6 ms) bi/triphasic motor unit potentials (MUPs) on submaximal effort apart from a decremental response on repetitive nerve stimulation (RNS) at 2 Hz. While electrophysiology is an important tool in the diagnosis of myasthenia gravis, pathological EMG patterns do not exclude the diagnosis of myasthenia gravis.

Management of critical illness polyneuropathy and myopathy

A syndrome of generalized weakness, areflexia, and difficulty with weaning from a ventilator is a common clinical presentation in the critically ill patient, especially in the setting of sepsis, multiorgan failure, and hyperglycemia. At first believed to be a manifestation of nerve (critical illness neuropathy, CIN) or muscle (critical illness myopathy, CIM) dysfunction, our current conceptualization is as a spectrum (critical illness neuromuscular abnormalities, CINMA) that varies in extent and site(s) of involvement, but often a similar clinical presentation. Signs and symptoms of CINMA must be identified early to foster recovery and limit morbidity and mortality. The medical history is crucial in excluding preexisting neuromuscular conditions and electrodiagnostic testing helps to establish the diagnosis and prognostication. A stepwise approach to the management of a patient with CINMA is outlined, but avoiding potential medications, and ensuring supportive care are the primary interventions to consider. Recently intensive insulin therapy for hyperglycemia has been shown to lower the risk of CINMA and decrease the time of ventilatory support, but with a greater risk of hypoglycemia. Future therapeutic interventions will require a better understanding of disease pathogenesis, but may target proinflammatory cytokine and free-radical pathways, muscle gene expression, ion channel function, or proteolytic muscle protein mechanisms. Rehabilitation is an equally essential component in a patient's management. Although prognosis depends on the extent of the underlying muscle and nerve damage, mild persistent deficits are common and severe disability may be persistent.

Autoimmune myasthenia gravis in a ferret

CASE DESCRIPTION

A 7-month-old neutered male ferret was evaluated for episodic pelvic limb weakness of 2 weeks' duration.

CLINICAL FINDINGS

Neurologic examination revealed flaccid tetraparesis with decreased spinal reflexes suggestive of a neuromuscular disease. Results of hematologic and CSF analyses, thoracic radiography, and abdominal ultrasonography were unremarkable. Electrodiagnostic testing revealed subtle spontaneous activity localized to pelvic limb interosseous muscles, unremarkable motor nerve conduction velocities, and lower than typical compound muscle action potential (CMAP) amplitude for tibial nerve stimulation only. A severe decremental response of the CMAP was detected with repetitive nerve stimulation (45.5% at the third ulnar nerve). An esophagogram revealed mild megaesophagus. Intravenous neostigmine methylsulfate administration resulted in immediate resolution of muscle weakness. Cross-reacting anti-acetylcholine receptor (AChR) antibodies were detected in serum (0.35 nmol/L) by use of a canine- and feline-specific muscle extract. Clinical signs and ancillary test results were diagnostic of acquired myasthenia gravis.

TREATMENT AND OUTCOME

Pyridostigmine bromide was administered (1 mg/kg [0.45 mg/lb], PO, q 8 h), resulting in complete remission of clinical signs. However, 1 month after the diagnosis, the ferret was euthanized because of recurrence of weakness despite anticholinesterase treatment.

CLINICAL RELEVANCE

To the authors' knowledge, this is the first report of acquired myasthenia gravis in a ferret and the first identification of anti-AChR antibodies in this species. Autoimmune myasthenia gravis should be considered in ferrets when weakness and flaccid paresis suggest a neuromuscular disease. Electrodiagnostic testing, anticholinesterase challenge, and AChR antibody titer determination were helpful for diagnosis of this condition.

Diagnostic value of the electromyography of the extraocular muscles

OBJECTIVE

The electromyography (EMG) of the extraocular muscles (EOM) represents a special form of electrophysiological investigation techniques which can be offered only in a few centers with special ophthalmologic and neurophysiologic expertise due to its special characteristics. The diagnostic value of the EOM-EMG is especially apparent in neuromuscular diseases which occur with predominantly ocular manifestation.

METHODS

Needle EMG examinations of EOM were performed in a cohort of 206 patients with a variety of relevant disorders mainly with a neurological focus. The results of these EMG examinations were assessed retrospectively. After local anaesthesia of the sclera and using a lid retractor to keep the eye open the EOM were identified visually by an experienced ophthalmologist and the needle was inserted. The EMG activity was registered in resting position, in mild volitional, and at maximum activation. The assessment was performed visually on a monitor by an experienced neurophysiologist.

RESULTS

In the group of neuromuscular (myopathic) diseases, the results of the EOM-EMG were compatible with the clinical diagnosis in 54 of 65 patients (83%) and in 69 of 85 patients (81%) in the group with peripheral lesions. In a "Varia" group (n=56) no diagnosis could be established despite all further investigations in 31 patients. In the remaining patients, the EOM-EMG result was compatible with the diagnosis in 22 of 25 patients (88%). Subgroup analysis revealed that particularly in myositis (30 of 33 findings in 32 patients, one patient was examined twice; 91%), muscle dystrophy (7 of 8 patients; 88%) and in isolated nerve lesions (64 of 79 patients; 81%) the diagnosis could be positively proven by the EOM-EMG. Clinically relevant complications were not observed.

CONCLUSIONS

The EOM-EMG is safe and has a high diagnostic value especially in diseases such as myositis, muscular dystrophy and isolated peripheral nerve lesions.

SIGNIFICANCE

With better knowledge of the diagnostic value of the EOM-EMG in various diseases, less relevant diagnostic investigations can be avoided in the future. Moreover, a higher degree of trust in the method should facilitate the decision to perform this special diagnostic method.

Phrenic nerve stimulation

Weakness of the limbs and respiratory muscles has increasingly been found to be a frequent event that complicates the medical history of patients in Intensive Care. The problem normally affects more serious cases and presents as muscular weakness leading to flaccid paralysis and difficulty in weaning patients off mechanical ventilation. This latter sign leads the intensivist to suspect possible involvement of the neuromuscular respiratory system. Unfortunately, in-depth clinical assessment of the neuromuscular respiratory system is difficult with critically ill patients, and electrophysiological studies have been used instead to overcome this problem. Of these latter, electric and electromagnetic stimulation of the phrenic nerve have been successful (along with needle electromyography of the diaphragm) in identifying the causes of neuromuscular respiratory insufficiency, especially in Intensive Care. In this brief chapter, we will be discussing the technique of electric stimulation of the phrenic nerve and neuromuscular respiratory insufficiency within the field of critical illness polyneuropathy.

Fiberoptic endoscopic evaluation of swallowing with simultaneous Tensilon application in diagnosis and therapy of myasthenia gravis

BACKGROUND

Dysphagia is a common symptom in myasthenia gravis (MG). Clinical examination alone fails to detect and grade myasthenic dysphagia sufficiently. For a more precise examination of swallowing function in myasthenia gravis additional technical tools are necessary.

OBJECTIVE

To investigate the diagnostic and therapeutic impact of fiberoptic endoscopic evaluation of swallowing with simultaneous Tensilon application (FEES-Tensilon Test) in myasthenia gravis.

METHODS

FEES-Tensilon Test was performed following a standardized protocol. Four severely affected patients with dysphagia as their leading symptom were examined. Dysphagia was characterized by five salient endoscopic findings: leakage, delayed swallowing reflex, penetration, aspiration and residues. If a normalisation or at least an improvement of swallowing function occurred shortly after Tensilon administration the FEES-Tensilon Test was rated as being positive.

RESULTS

In three patients the FEES-Tensilon Test successfully detected MG-related dysphagia. In one patient with dysphagia caused by oculopharyngeal muscular dystrophy the FEES-Tensilon Test was truly negative. Beside an early diagnosis of MG-related dysphagia, the FEES-Tensilon Test was useful in the differentiation between myasthenic and cholinergic crisis and in guiding treatment decisions. In all patients the FEES-Tensilon Test was superior to clinical evaluation of dysphagia. No severe side effect occurred while performing the FEES-Tensilon Test.

CONCLUSION

The FEES-Tensilon Test is a suitable tool in the diagnosis and therapy of myasthenia gravis with pharyngeal muscles weakness.

A Diagnostic and Management Dilemma

BACKGROUND

Neuromuscular junction disorders are usually categorized as either presynaptic or postsynaptic. The most frequently encountered disorder of the postsynaptic neuromuscular junction is acquired myasthenia gravis. Lambert-Eaton myasthenic syndrome is a well-known prototype of the presynaptic autoimmune disorders of neuromuscular transmission. These major disorders of neuromuscular transmission are relatively common and distinctly recognized, but co-occurrence of these disorders (overlap myasthenic syndrome) is rare and has so far attracted little attention.

REVIEW SUMMARY

This report describes a patient with acquired myasthenia gravis and immunologic coexistence of Lambert-Eaton myasthenic syndrome (overlap myasthenic syndrome) in association with abdominal/uterine leiomyosarcoma. The patient presented with acute respiratory failure, making identification and management of her illness challenging. A general overview of the complexities associated with overlap between myasthenia gravis and Lambert-Eaton myasthenic syndrome is provided and this patient's complicated clinical course and response to therapy are discussed.

CONCLUSION

To our knowledge, this is the first report of overlap myasthenic syndrome in conjunction with abdominal leiomyosarcoma. The immunologic coexistence of acquired myasthenia gravis and Lambert-Eaton myasthenic syndrome in a patient with a malignant smooth-muscle tumor is intriguing and suggests that a common paraneoplastic process targeting 2 different onconeural antigens was the underlying pathogenic mechanism in this patient.

Syndrome de Lambert-Eaton et neuroblastome chez l'enfant : à propos de 2 observations

Lambert-Eaton myasthenic syndrome is a paraneoplasic syndrome which can reveal a primitive tumor. Frequently, the first diagnosis is myasthenia gravis. This disease is extremely rare in children. Only 10 cases have been reported in the last 35 years. We report 2 new observations occurring in very young patients, aged 2 and 3 years, with a ganglioneurobastoma as primitive tumor.

Neuromuscular manifestations of critical illness

Critical illness, more precisely defined as the systemic inflammatory response syndrome (SIRS), occurs in 20%-50% of patients who have been on mechanical ventilation for more than 1 week in an intensive care unit. Critical illness polyneuropathy (CIP) and myopathy (CIM), singly or in combination, occur commonly in these patients and present as limb weakness and difficulty in weaning from the ventilator. Critical illness myopathy can be subdivided into thick-filament (myosin) loss, cachectic myopathy, acute rhabdomyolysis, and acute necrotizing myopathy of intensive care. SIRS is the predominant underlying factor in CIP and is likely a factor in CIM even though the effects of neuromuscular blocking agents and steroids predominate in CIM. Identification and characterization of the polyneuropathy and myopathy depend upon neurological examination, electrophysiological studies, measurement of serum creatine kinase, and, if features suggest a myopathy, muscle biopsy. The information is valuable in deciding treatment and prognosis.

Clinical utility of videofluorography with concomitant Tensilon administration in the diagnosis of bulbar myasthenia gravis

Myasthenia gravis (MG) classically presents with ocular, bulbar, and predominantly proximal muscle weakness. Isolated bulbar symptoms occur in less than 25% of cases and can mimic stroke (1-3). If left untreated, MG can lead to significant morbidity and mortality, including myasthenic crisis and recurrent aspiration pneumonia. We describe a case of a 68-year-old man who presented with isolated bulbar symptoms. We used a novel approach to diagnosis which included a videofluorographic swallow study with concomitant Tensilon (edrophonium) injection.

Myasthenia Gravis

Myasthenia gravis is a disorder of neuromuscular transmission, manifest by variable weakness of skeletal muscle. The disorder has a range of therapies that differ with respect to efficacy, timing, and side effects. The physician treating myasthenia gravis must be well versed in understanding the evidence basis for using these agents, as well as the trade-offs between persistent disease manifestations and their costs and expected benefits. Diagnosis of myasthenia gravis depends on recognizing the pattern of weakness, which typically involves some combination of extraocular, bulbar, facial, limb, and neck muscles. Management relies on some combination of medications that influence the function of the neuromuscular junction and treatments that alter the immune response. Thymectomy is commonly used, although trends in evidence-based medicine are leading expert clinicians to look closely at its efficacy. Plasma exchange is useful for patients in crisis, who require rapid improvement. The exact role for high-dose intravenous immunoglobulin in this setting is still being studied, although the agent is gaining popularity. Knowing that the treatments are effective is not enough. It is still important to determine the treatment that has a more rapid onset, because these patients often require intensive care or respiratory assistance.

Myasthenia gravis

BACKGROUND

In myasthenia gravis (MG), the prototypic autoimmune disease, antibodies against acetylcholine receptors impair neuromuscular transmission and produce weakness. Although recognized for several hundred years, it has only been over the last three decades that effective treatments have become available for MG.

REVIEW SUMMARY

This review summarizes the principles of normal neuromuscular transmission, the clinical features of MG, and the tests available for its diagnosis. The current treatments for MG are discussed, including possible mechanisms of action and a discussion of potential adverse effects. When available, evidence-based justification for individual treatment options is given, and areas of controversy identified.

CONCLUSIONS

Significant improvements in the diagnosis and management of MG have been made over the last several decades. The available treatments either improve neuromuscular transmission directly, or suppress or modulate the pathogenic immune response in MG. Treatment is highly individualized and must take into account the severity of disease, the presence of other diseases, and the kinetics of response for the available treatments. This requires detailed knowledge of the mechanisms of action and possible adverse effects for each treatment. However, despite an optimistic outlook with modern treatment, the management of MG continues to be plagued by lack of efficacy in some, and significant adverse effects in most MG patients.

An unusual cause of third nerve palsy

A74-year-old Caucasian, non-hypertensive, non-diabetic, otherwise fit male presented to the outpatient department with a 1-week history of painless left ptosis and diplopia of gradual onset. There were no other neurological symptoms.

Examination revealed partial left third nerve palsy (i.e. ptosis, eyeball fixed down and outward but with normal reacting pupil). There was no other neurological deficit and systemic examination was normal.

Investigations revealed normal full blood counts, erythrocyte sedimentation rate, glucose, electrolytes, thyroid function test, serum immunoglobulins, chest X-ray and negative antinuclear and rheumatoid factor. Computed tomography brain scan with contrast enhancement was normal. The third nerve palsy improved spontaneously to normal over a period of 3–4 weeks.

The patient re-presented 2 months later, this time with features of gradual painless partial right third nerve palsy (ptosis, eyeball fixed down and out with normally reacting pupil). Again there was no further neurological deficit and systemic examination was normal.

Following this assessment, the anatomy of the third cranial nerve was considered in detail leading to a positive Tensilon test to confirm the diagnosis of ocular myasthenia gravis. Computed chest scan did not reveal any evidence of thymoma. Anti-acetylcholine receptor antibodies were absent. He has remained well on a small dose of pyridostigmine.